

A comparative study between different types of umbilical cord stem cells in treatment of experimental diabetic rats

A thesis submitted for the partial fulfillment of M.Sc. Degree in
Pharmaceutical Sciences (Biochemistry)

By

Rasha Farouk El-Demerdash

Teaching Assistant of Biochemistry, Faculty of Pharmacy
Misr International University

Under supervision of

Prof. Dr. Hala Osman El-Mesallamy

Professor of Biochemistry
Vice Dean for Postgraduate Studies and Research
Faculty of Pharmacy, Ain Shams University

Prof. Dr. Lamiaa Nabil Hammad

Professor of Biochemistry
Head of Pharmacology and Toxicology Department
Faculty of Pharmacy, Misr International University

Dr. Mohamed Mostafa Mohamed Kamal

Lecturer of Biochemistry
Biochemistry Department
Faculty of Pharmacy, Ain Shams University

Biochemistry Department

Faculty of Pharmacy

Ain Shams University

2014

رسالة توطئة للحصول على درجة الماجستير في العلوم الصيدلانية
(تخصص كيمياء حيوية)

!!! !! !!!!! !!!!!!! !!!Š!!!!!!

!!š!!!!!!!!!!!! !!!!! !!!!! !!!!!

š!! !!!!! ! !š! !! !š! !! !!!š!!

!!

أ.د. هالة عثمان المسلمي

أستاذ الكيمياء الحيوية
وكيل الكلية للدراسات العليا والبحوث
كلية الصيدلة - جامعة عين شمس

استاذ الكيمياء الحيوية
رئيس قسم الادوية والسموم
كلية الصيدلة - جامعة مصر الدولية

مدرس الكيمياء الحيوية
قسم الكيمياء الحيوية
كلية الصيدلة - جامعة عين شمس

قسم الكيمياء الحيوية
كلية الصيدلة
جامعة عين شمس
٢٠١٤

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

فَإِنَّ اللَّهَ يُدْخِلُ الْمُؤْمِنِينَ وَالْمُتَّقِينَ الْفِرْدَوْسَ الْأَعْلَى الَّذِي لَا يُدْخِلُ فِيهِ الْفَاسِقِينَ

صَدَقَ اللَّهُ الْعَظِيمَ

ACKNOWLEDGEMENTS

First and foremost, Thanks are due to **Allah**.

I am much honored to have **Prof. Dr. Hala El-Mesallamy**, Vice Dean for Postgraduate Studies and Research, Faculty of Pharmacy, Ain-Shams University, as my supervisor. She has showed me different ways to approach research problems and the need to be persistent to accomplish any goal. I would like to thank her for her active supervision, constructive criticism, insightful comments, guidance throughout the work and efforts in revising the manuscript. I am indebted for Dr. Hala the proposal of the point, enlightening thoughts, and general encouragement.

My deepest gratitude is to my supervisor **Prof. Dr. Lamiaa Hammad**, Head of Pharmacology and Toxicology, Faculty of Pharmacy, Misr International University, for her continuous support. She has been always there to listen and to give advice. She has taught me how to have self-confidence especially when I doubted myself, and brought out the best of me. Without her encouragement, constant guidance and her tender loving care, I could not have finished this dissertation. Dr. Lamiaa is and will always be a guide and a mentor.

Words cannot express my deep gratitude and sincere appreciation to my, **Dr. Mohamed Mostafa Kamal**, Lecturer of Biochemistry, Faculty of Pharmacy, Ain-Shams University. I have been amazingly fortunate to have a supervisor who gave me the freedom to explore on my own and at the same time the guidance to recover when my steps faltered. I am grateful to him for holding me to a high research standard and enforcing strict validations for each research result, and thus teaching me how to do research. Dr. Mohamed taught me how to question thoughts and express ideas. His patience and support helped me overcome many crisis situations and finish this dissertation. I hope that one day I would become as good an advisor to my students as Dr. Mohamed has been to me.

Acknowledgments

I am grateful to **Prof. Dr. Adel M. Bakeer**, Professor of Pathology, Faculty of Veterinary Medicine, Cairo University, for his kind help in performing histopathological studies and interpretation of their results. Also, I would like to extend my cordial appreciation to **Dr. Abd El-Latif El-Kholy**, Assistant Professor of Gynecology, Faculty of Medicine, Ain-Shams University, for his generous help, and his unlimited effort in collecting the required umbilical cord blood samples. Also, I am thankful to **Dr. Rabab Hawary**, Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, for the generous help in using the flowcytometry analysis unit.

I would like to offer my heartfelt gratitude to my colleague **Dina Hamada**, Assistant Lecturer of Biochemistry, Faculty of Pharmacy, Ain-Shams University, not only for providing Wharton Jelly cells, but also for her encouragement, insightful comments, and for listening to my complaints and frustrations.

Last, but not least, I thank my parents, for giving me life in the first place, educating me, their unconditional support and encouragement to pursue my interests, even when the interests went beyond boundaries of language, field and geography. I am grateful to my **husband, son and siblings** who have shared me all the long journey and have been there for me all along the road ahead.

TABLE OF CONTENTS



Subjects	Page number
Publications Related to the Thesis	III
List of Abbreviations	V
List of Figures	VII
List of Tables	IX
Introduction and Aim of Work	1
Review of Literature	
I. Diabetes mellitus (DM)	4
A. Definition and epidemiology	4
B. Classification	4
C. Signs and symptoms	7
D. Treatment	7
II. Stem cell	9
A. Stem cell therapy	9
B. Classification of stem cells according to their proliferation and potency	11
C. Classification of stem cells according to their source's developing stage	13
III. Umbilical cord (UC) stem cells	16
A. Sources of stem cells within the UC	17
B. Advantages of UC stem cells	19
IV. Mesenchymal stem cells' (MSCs) therapy	21
A. Sources and definition by International Society for Cellular Therapy (ISCT)	21
B. Therapeutic potential of MSCs in many diseases	23
C. Role of MSCs in type 1 DM therapy	25

Table of Contents

Materials and Methods	30
I. Isolation of human umbilical cord blood mononuclear cells (UCB-MNCs), culture and expansion of UCB-MSCs	32
II. Culture and expansion of cryopreserved Wharton's Jelly (WJ)-MSCs	39
III. Characterization of the isolated and cultured cells	39
IV. Differentiation of UCB-MSCs and WJ-MSCs into insulin producing cells (IPCs) in vitro	42
V. Assessment of the in vitro differentiation potential of UCB-MSCs and WJ-MSCs into IPCs	44
VI. Assessment of therapeutic potential of UCB-MSCs and WJ-MSCs in streptozotocin (STZ) induced diabetic rats (In vivo)	55
VII. Statistical analyses	58
Results	
I. Isolation of human UCB-MNCs, culture and expansion of UCB-MSCs and cryopreserved WJ-MSCs	59
II. Characterization of the of the isolated and cultured cells	59
III. Assessment of in vitro differentiation of UCB-MSCs and WJ-MSCs into IPCs	65
IV. The therapeutic potential of UCB-MSCs and WJ-MSCs in STZ-induced diabetic rats	73
Discussion	78
Summary and Conclusions	90
Recommendations	94
References	95
Appendix	117-132
Arabic Summary	

Publications related to the Thesis

I. Poster presented in 20th ISCT Annual Meeting April 23-26, 2014, Paris, France

	Cytotherapy Volume 16, Issue 4, Supplement, April 2014, Pages S66 20th Annual ISCT Meeting	
---	---	---

Comparing umbilical cord blood stem cells and wharton's jelly mesenchymal stem cells regarding their differentiation potential to insulin producing cells

M.M. Kamal¹, H.O. El-Mesallamy¹, L.N. Hammad², R.F. El-Demerdash²

[Show more](#)

DOI: 10.1016/j.jcyt.2014.01.241 [Get rights and content](#)

Introduction

The number of patients suffering from Diabetes Mellitus (DM) is growing in an alarming rate which makes DM the most prevalent and serious metabolic disease. Now, cell therapy treatment options for diabetic patients are under extensive study. Interestingly, umbilical cord (UC) has been proved to be a good source of mesenchymal stem cells (MSCs), namely from umbilical cord blood (UCB-MSCs) and Wharton's jelly (WJ-MSCs).

Objectives

We thought to investigate the difference between these 2 important banking sources of stem cells and to compare their differentiation potentials towards insulin producing cells (IPCs) in vitro and their potential use for treatment of streptozotocin (STZ) induced diabetic rats in vivo.

Materials and methods


Both UCB-MSCs and WJ-MSCs were isolated from UC and expanded for several passages. Expression of typical MSCs surface antigens and adipogenic differentiation potential as an example of mesenchymal lineage was used to verify MSCs identity. Afterwards, both UCB-MSCs and WJ-MSCs were induced to differentiate into IPCs, then the differentiated cells were assessed both genetically by determining the expression of Nestin, as stem cell marker and key markers of mature β -cells such as Pdx-1, Mafa and Nkx2.2 using qRT-PCR, and functionally by measuring insulin secretion after glucose challenge (Glucose stimulated insulin secretion; GSIS); a hall mark of functional β -cells.

Results and conclusions

WJ appeared to be a much more homogenous and potential source for MSCs as compared to UCB. Interestingly, both UCB-stem cells and WJ-MSCs were successfully differentiated to IPCs. Yet, the resulting IPCs from WJ-MSCs were to a limited extent functioning better than those obtained from UCB-MSCs. Both cell types were able to decrease fasting blood glucose level transiently in STZ induced diabetic mice. Taken together, we can conclude that WJ could represent a potential source of cells in the field of DM cell therapy rather than UCB.

Copyright © 2014 Published by Elsevier Inc.

**II. Poster presented in EMBO/EMBL
Symposium-Translating Diabetes
April 30-May 3, 2014, Heidelberg, Germany**



**The generation of insulin producing cells from Wharton's
jelly mesenchymal stem cells in comparison to umbilical
cord blood mesenchymal stem cells**

Introduction: The number of patients suffering from Diabetes Mellitus (DM) is growing in an alarming rate which makes DM the most prevalent metabolic disease. Now, cell therapy treatment options for diabetic patients are under extensive study. Interestingly, umbilical cord (UC) has been proved to be a good source of mesenchymal stem cells (MSCs), namely; umbilical cord blood (UCB-MSCs) and Wharton's jelly (WJ-MSCs).

Objectives: we thought to investigate the difference between these 2 important banking sources of stem cells and to compare their differentiation potentials towards insulin producing cells (IPCs) invitro and their potential use for treatment of streptozotocin-induced diabetic rats invivo.

Materials and methods: Both UCB-MSCs and WJ-MSCs were isolated from UC and expanded for several passages. Expression of typical MSCs surface antigens and adipogenic differentiation potential as an example of mesenchymal lineage was used to verify MSCs identity. Afterwards, both UCB-MSCs and WJ-MSCs were induced to differentiate into IPCs, then the differentiated cells were assessed both genetically by determining the expression of Nestin, as stem cell marker and key markers of mature β -cells such as Pdx-1, Mafa and Nkx2.2 using qRT-PCR, and functionally by measuring insulin secretion after glucose challenge (Glucose stimulated insulin secretion; GSIS); a hall mark of functional β -cells.

Results and conclusions: WJ appeared to be a much more homogenous and potential source for MSCs as compared to UCB. Interestingly, both UCB-stem cells and WJ-MSCs were successfully differentiated to IPCs. Yet, the resulting IPCs from WJ-MSCs were to a limited extent functioning better than those from UCB-MSCs. Both cell types were able to decrease fasting blood glucose level transiently in diabetic rats, yet WJ-MSCs showed an earlier more sustained effect. Taken together, we can conclude that WJ could represent a potential source of cells in the field of DM cell therapy rather than UCB.

LIST OF ABBREVIATIONS

ANOVA	Analysis of variance
ASCs	Adult stem cells
BM	Bone marrow
BW	Body weight
CB	Cord blood
CD	Clusters of differentiation
cDNA	Complementary deoxy nucleic acid
Ct	Cycle threshold
DM	Diabetes mellitus
DMEM	Dulbecco's modified Eagle's medium
dNTP	Deoxy nucleotide tri-phosphate
ELISA	Enzyme linked immuno-sorbent assay
ESC s	Embryonic stem cells
FACS	Fluorescence-activated cell sorting
FBG	Fasting blood glucose
FBS	Fetal bovine serum
FITC	Fluorescein isothiocyanate
GDM	Gestational diabetes mellitus
GSIS	Glucose stimulated insulin secretion
GVHD	Graft-versus-host disease
H&E	Hematoxylin and eosin stain
HG-DMEM	High glucose- Dulbecco's modified Eagle's medium
HG-KRB	High glucose-Kreb's ringer bicarbonate
HLA	Human leukocyte antigen
HSCs	Hematopoietic stem cells
IDDM	Insulin dependent diabetes mellitus
IDF	International diabetes federation
Ig	Immunoglobulin
IPCs	Insulin producing cells
IR	Insulin resistance
ISCT	International society for cellular therapy
Isl-1	Insulin gene enhancer protein
KRB	Kreb's ringer bicarbonate

List of Abbreviations

LG- KRB	Low glucose-Kreb's ringer bicarbonate
LG-DMEM	Low glucose-Dulbecco's modified Eagle's medium
MafA	V-maf musculoaponeurotic fibrosarcoma oncogene homolog
MHC	Major histocompatibility complex
MNCs	Mononuclear cells
MSCs	Mesenchymal stem cells
NA	Nicotinamide
Ngn-3	Neurogenin-3
NIDDM	Non-insulin dependent diabetes mellitus
P	Passage
PBS	Phosphate-buffered saline
PCR	Polymerase chain reaction
Pdx-1	Pancreatic and deodenal homebox 1
PE	Phycoerythrin
Pen/Strep/Ampho	Penicillin /streptomycin /amphotercin B
qRT-PCR	Quantitative reverse transcriptase polymerase chain reaction
RNase	Ribonuclease enzyme
RT	Reverse transcriptase enzyme
STZ	Streptozotocin
Taq	<i>Thermusaquaticus</i>
UC	Umbilical cord
UCB	Umbilical cord blood
UCWJ	Umbilical cord Wharton's jelly
WHO	World health organization
WJ	Wharton's jelly
α-MEM	Alpha minimum essential medium

LIST OF FIGURES

Figure number	Figure title	Page
Figure (1)	<i>Pathogenesis of IDDM</i>	5
Figure (2)	<i>Pathogenesis of NIDDM</i>	6
Figure (3)	<i>Pluripotent stem cells are capable of forming tissues originating in the three embryonic layers</i>	12
Figure (4)	<i>Perinatal tissues</i>	15
Figure (5)	<i>Compartments within the human UC</i>	17
Figure (6)	<i>Different sources of MSCs; MSCs can be derived from several adult or infant tissues</i>	22
Figure (7)	<i>Immunomodulatory effect of MSCs</i>	24
Figure (8)	<i>Different routes of MSCs /IPCs administration in rats/ mice</i>	27
Figure (9)	<i>In vivo collection of human UCB</i>	33
Figure (10)	<i>Buffy coat at plasma/histopaque interface after density gradient Ficoll centrifugation of UCB</i>	34
Figure (11)	<i>Filling the hemocytometer chamber with cell sample diluted by trypan blue</i>	36
Figure (12)	<i>Standard calibration curve for insulin</i>	54
Figure (13)	<i>Phase contrast images of cultured UCB cells (a): P0 & (b): P1</i>	60
Figure (14)	<i>Phase contrast images of cultured WJ cells (a): P0 & (b): P1</i>	60
Figure (15)	<i>Immunophenotyping of (a):UCB-MNCs and (b):UCB-MSCs and (c):WJ-MSCs</i>	63
Figure (16)	<i>Adipogenic differentiation of CB-MSCs and WJ-MSCs</i>	64
Figure (17)	<i>Phase contrast images of differentiated UCB-MSCs and WJ-MSCs to their control cells.</i>	65

List of Figures

Figure (18)	<i>Relative mRNA expression of Nestin throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	66
Figure (19a)	<i>Relative mRNA expression of Pdx-1, throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	67
Figure (19b)	<i>Relative mRNA expression of MafA throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	67
Figure (19c)	<i>Relative mRNA expression of Ngn-3, throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	68
Figure (19d)	<i>Relative mRNA expression of Nkx2.2 throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	68
Figure (19e)	<i>Relative mRNA expression of Isl-1 throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	69
Figure (20)	<i>Fold change of mRNA relative expression level of β-cells genes throughout the differentiation protocol of UCB-MSC into IPCs</i>	70
Figure (21)	<i>Fold change of mRNA relative expression level of β-cells genes throughout the differentiation protocol of WJ-MSC into IPCs</i>	70
Figure (22)	<i>In vitro GSIS assay of differentiated UCB-MSCs and WJ-MSCs</i>	72
Figure (23)	<i>FBG levels of STZ-induced diabetic rats for 2 months post transplantation UCB-MSCs and WJ-MSCs</i>	74
Figure (24)	<i>BW change of STZ-induced diabetic rats for 2 months post transplantation UCB-MSCs and WJ-MSCs</i>	75
Figure (25)	<i>Histology of various organs in normal, diabetic and MSCs treated diabetic rats</i>	77

LIST OF TABLES

Table number	Table title	Page
Table (1)	<i>Preparation of complete α-MEM</i>	41
Table (2)	<i>Media throughout the 3 steps differentiation protocol of MSCs into IPCs</i>	43
Table (3)	<i>cDNA synthesis master mix volumes</i>	48
Table (4)	<i>qRT-PCR reaction mix</i>	49
Table (5)	<i>Forward and Reverse primers used in qRT-PCR reaction</i>	50
Table (6)	<i>CDs expression in UCB-MNCs, UCB-MSCs and WJ-MSCs</i>	62
Table (A1)	<i>Relative mRNA expression of Nestin throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	117
Table (A2)	<i>Relative mRNA expression of Pdx-1 throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	118
Table (A3)	<i>Relative mRNA expression of MafA throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	119
Table (A4)	<i>Relative mRNA expression of Ngn-3 throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	120
Table (A5)	<i>Relative mRNA expression of Nkx2.2 throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	121
Table (A6)	<i>Relative mRNA expression of Isl-1 throughout the differentiation protocol of UCB-MSCs and WJ-MSCs into IPCs</i>	122
Table (A7)	<i>Levels of Insulin secreted from both differentiated UCB-MSCs and WJ-MSCs in response to in vitro glucose challenge</i>	123

List of Tables

Table (A8)	<i>FBG of diabetic/DMEM (control) rats group every 10 days interval for 2 months post transplantation</i>	124
Table (A9)	<i>FBG of diabetic/UCB-MSCs rats group every 10 days interval for 2 months post transplantation</i>	125
Table (A10)	<i>FBG of diabetic/WJ-MSCs rats group every 10 days interval for 2 months post transplantation</i>	126
Table (A11)	<i>BW of diabetic/DMEM (control) rats group every 10 days interval for 2 months post transplantation</i>	127
Table (A12)	<i>Changes in BW of diabetic/DMEM (control) rats group every 10 days interval for 2 months post transplantation</i>	128
Table (A13)	<i>BW of diabetic/UCB-MSCs rats group every 10 days interval for 2 months post transplantation</i>	129
Table (A14)	<i>Changes in BW of diabetic/UCB-MSCs rats group every 10 days interval for 2 months post transplantation</i>	130
Table (A15)	<i>BW of diabetic/WJ-MSCs rats group every 10 days interval for 2 months post transplantation</i>	131
Table (A16)	<i>Changes in BW of diabetic/WJ-MSCs rats group every 10 days interval for 2 months post transplantation</i>	132